Achilles Therapeutics plc - American Depositary Shares (ACHL)
1.3850
-0.0050 (-0.36%)
Achilles Therapeutics is a biotechnology company focused on developing innovative cancer therapies that harness the power of the immune system
The company specializes in creating personalized T-cell therapies, which are designed to target and destroy tumor cells by identifying unique neoantigens present in an individual’s cancer. By leveraging advances in genomics and immunotherapy, Achilles aims to improve treatment outcomes for patients with various types of cancer, while minimizing the side effects commonly associated with traditional treatments. Through its research and development efforts, the company is dedicated to transforming the landscape of cancer care.
Shares of Achilles Therapeutics plc (NASDAQACHL) are surging following a major strategic announcement from the company. The biotechnology firm revealed plans to discontinue its TIL-based cNeT program and close its ongoing Phase I/IIa clinical trials, CHIRON and THETIS.
U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88. The S&P 500 also fell, dropping, 0.28% to 5,197.03.
Shares of STAAR Surgical Company (NASDAQSTAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3% to $44.30 on Thursday.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P 500 also rose, gaining, 0.75% to 5,250.72.
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference:
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies
NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector. Consequently, many small and micro-cap biotech companies are trading at all-time lows, with several down by over 80-90% in recent years. This downturn has led to many biotech firms trading below their cash holdings.
NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (“ODD”) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQGNPX) ( Profile ) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (“SCLC”). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.’s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC NASDAQ: JAZZNASDAQJAZZ)(NASDAQ: ALXONASDAQALXO and Achilles Therapeutics PLC (NASDAQ: ACHLNASDAQ) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.
